Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.53 |
| ▸ | TERT | O14746 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 9/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956446 | 0.94 | TBXAS1 (0.56) | TBXAS1TERTALOX15TAAR1FDPS | |
| SCHEMBL238669 | 0.93 | TBXAS1 (0.58) | TBXAS1TERTALOX15TAAR1FDPS | |
| SCHEMBL301422 | 0.88 | — | — | |
| SCHEMBL3431746 | 0.81 | TBXAS1 (0.66) | TBXAS1TERTALOX15TAAR1FDPS | |
| SCHEMBL9777191 | 0.81 | TBXAS1 (0.60) | TBXAS1TERTALOX15TAAR1FDPS | |
| SCHEMBL27582835 | 0.81 | TBXAS1 (0.49) | TBXAS1TERTALOX15TAAR1FDPS | |
| SCHEMBL288127 | 0.80 | TBXAS1 (0.49) | TBXAS1TERTALOX15TAAR1NAMPT | |
| SCHEMBL503743 | 0.79 | TBXAS1 (0.69) | TBXAS1TERTALOX15TAAR1FDPS | |
| SCHEMBL28062565 | 0.79 | TBXAS1 (0.69) | TBXAS1TERTALOX15TAAR1FDPS | |
| SCHEMBL9112933 | 0.78 | TBXAS1 (0.46) | TBXAS1TERTALOX15TAAR1FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-8735599-B2 | Substituted imidazole derivates | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8735599-B2 | Substituted imidazole derivates | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| WO-2013077989-A1 | PROCESS FOR PREPARATION OF ALUMINUM SALT OF PHOSPHONIC ACID ESTER | ICL-IP AMERICA INC. (US) | 2013-05-30 | — | — | WO | disclosed |
| EP-1765789-B1 | N-(1-(1-BENZYL-4-PHENYL-1H-IMIDAZOL-2-YL)-2,2-DIMETHYLPROPYL)BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS KINESIN SPINDLE PROTEIN (KSP) INHIBITORS FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2013-02-27 | — | — | EP | disclosed |
| US-20130017196-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES | CHIRON CORPORATION | 2013-01-17 | — | — | US | disclosed |
| US-20130017196-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES | CHIRON CORPORATION | 2013-01-17 | — | — | US | disclosed |
| US-8318791-B2 | Substituted imidazole derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318791-B2 | Substituted imidazole derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20090258016-A1 | Substituted imidazole derivatives | WANG WEIBO | 2009-10-15 | — | — | US | disclosed |
| US-20090258016-A1 | Substituted imidazole derivatives | WANG WEIBO | 2009-10-15 | — | — | US | disclosed |
| US-7576221-B2 | N-(3-aminopropyl)-N-[(1R)-1-(1-benzyl-4-phenyl-1H-imidazol-2-yl)-2-methylpropyl]-4-methylbenzamide; kinesin-related proteins (KRP) inhibitors; anticarcinogenic agent | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576221-B2 | N-(3-aminopropyl)-N-[(1R)-1-(1-benzyl-4-phenyl-1H-imidazol-2-yl)-2-methylpropyl]-4-methylbenzamide; kinesin-related proteins (KRP) inhibitors; anticarcinogenic agent | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1318996-B1 | SUBSTITUTED IMIDAZOLES AS DUAL HISTAMINE H1 AND H3 AGONISTS OR ANTAGONISTS | SCHERING CORP (US) | 2004-12-01 | — | — | EP | disclosed |
| US-6762186-B2 | USE TO TREAT ALLERGY, NASAL CONGESTION, INFLAMMATORY AND CENTRAL NERVOUS SYSTEM-RELATED DISEASES | SCHERING CORPORATION | 2004-07-13 | — | — | US | disclosed |
| CN-1461304-A | Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists | SCHERING CORP (US) | 2003-12-10 | — | — | CN | disclosed |
| EP-1318996-A2 | SUBSTITUTED IMIDAZOLES AS DUAL HISTAMINE H1 AND H3 AGONISTS OR ANTAGONISTS | Schering Corporation (US) | 2003-06-18 | — | — | EP | disclosed |
| US-20020082278-A1 | Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists | SCHERING CORPORATION | 2002-06-27 | — | — | US | disclosed |
| WO-2002044141-A2 | SUBSTITUTED IMIDAZOLES AS DUAL HISTAMINE H1 AND H3 AGONISTS OR ANTAGONISTS | SCHERING CORPORATION (US) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082278-A1 | Substituted imidazoles as dual histamine H1 and H3 agonists or antagonists | HRH3, HRH4, HRH2 | TBXAS1 2176/4885TERT 4612/4885ALOX15 3236/4885 |
| US-20090258016-A1 | Substituted imidazole derivatives | ABCG2, CYP2C19, AADAC | TBXAS1 900/4885TERT 3877/4885ALOX15 4559/4885 |
| US-20130017196-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES | ABCG2, CYP2C19, AADAC | TBXAS1 900/4885TERT 3877/4885ALOX15 4559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.